Travere Therapeutics, Inc. (TVTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Travere Therapeutics reported revenue of $490.7M, up 110.5% from $233.2M the year before. Net income was -$25.5M (a -5.2% net margin), or -$0.29 per diluted share. Gross margin was 97.9% and operating margin was -12.8%. Operating activities generated $37.8M of cash. At fiscal year end, Travere Therapeutics held $605.2M in total assets against $490.4M in total liabilities, including $93.0M of cash and equivalents.
Open the full interactive Travere Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Travere Therapeutics Key Stats
| Share Price | $51.80 |
|---|---|
| Market Cap | $4.84B |
| Revenue YoY Growth | +110.5% |
| 52-Week Range | $26.14 – $67.52 |
| Shares Outstanding | 93.5 million (basic, 2026 Q2) |
Travere Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $198.3M | $227.5M | $212.0M | $145.2M | $233.2M | $490.7M |
| Cost of Goods Sold | $6.1M | $6.8M | $7.6M | $11.4M | $7.7M | $10.3M |
| Gross Profit | $192.2M | $220.7M | $204.4M | $133.8M | $225.4M | $480.4M |
| Operating Income | -$176.2M | -$161.8M | -$266.6M | -$388.1M | -$323.8M | -$62.8M |
| Pre-Tax Income | -$188.8M | -$179.7M | -$278.2M | -$376.1M | -$320.5M | -$49.3M |
| Income Tax | -$19.4M | $409,000 | $313,000 | $223,000 | $120,000 | $988,000 |
| Net Income | -$169.4M | -$180.1M | -$278.5M | -$111.4M | -$321.5M | -$25.5M |
| Diluted EPS | -$3.56 | -$3.01 | -$4.37 | -$1.50 | -$4.08 | -$0.29 |
Travere Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $164.9M | $129.7M | $127.2M | $169.6M |
| Net Income | $25.7M | $2.7M | -$37.1M | -$34.8M |
| Diluted EPS | $0.28 | $0.03 | -$0.40 | -$0.37 |
Travere Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $84.8M | $165.8M | $61.7M | $58.2M | $58.5M | $93.0M |
| Current Assets | $410.4M | $582.8M | $486.4M | $616.8M | $416.7M | $437.6M |
| Total Assets | $607.4M | $776.6M | $672.6M | $788.9M | $594.1M | $605.2M |
| Current Liabilities | $92.7M | $124.1M | $142.2M | $177.9M | $200.8M | $159.9M |
| Total Long-Term Debt | $215.3M | $226.6M | $375.5M | $377.3M | $379.0M | $311.7M |
| Total Liabilities | $396.2M | $474.5M | $629.7M | $588.1M | $535.0M | $490.4M |
| Shareholders' Equity | $211.2M | $302.1M | $42.9M | $200.8M | $59.1M | $114.8M |
Travere Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$42.7M | -$14.8M | -$186.3M | -$280.0M | -$237.5M | $37.8M |
| Cash From Investing | -$61.3M | -$137.6M | -$32.6M | $55.8M | $99.3M | $27.9M |
| Cash From Financing | $127.7M | $231.7M | $117.6M | $218.8M | $139.4M | -$33.5M |
| Free Cash Flow | -$49.5M | -$19.9M | -$186.5M | -$280.7M | — | — |
Figures from Travere Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Travere Therapeutics financials page for every line item.
Travere Therapeutics Company Profile
| Ticker | TVTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001438533 |
Frequently Asked Questions
What was Travere Therapeutics' revenue in fiscal 2025?
Travere Therapeutics (TVTX) reported revenue of $490.7M for fiscal 2025.
What is Travere Therapeutics' annual revenue history?
Travere Therapeutics' annual revenue by fiscal year: 2020: $198.3M; 2021: $227.5M; 2022: $212.0M; 2023: $145.2M; 2024: $233.2M; 2025: $490.7M.
What was Travere Therapeutics' net income in fiscal 2025?
Travere Therapeutics reported net income of -$25.5M for fiscal 2025.
What was Travere Therapeutics' earnings per share (EPS) in fiscal 2025?
Travere Therapeutics' diluted EPS was -$0.29 for fiscal 2025 (adjusted for any later stock splits).
What was Travere Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Travere Therapeutics reported revenue of $169.6M.
How much debt does Travere Therapeutics have?
Travere Therapeutics reported $311.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Travere Therapeutics are outstanding?
Travere Therapeutics reported a weighted average of 93.5 million basic shares outstanding in 2026 Q2.
What is Travere Therapeutics' market cap?
Based on its latest closing price, Travere Therapeutics (TVTX) has a market capitalization of about $4.84B.
When does Travere Therapeutics' fiscal year end?
Travere Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Travere Therapeutics headquartered?
Travere Therapeutics lists its business address in San Diego, California in its SEC filings.